From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Mercer Global Advisors Inc. ADV boosted its holdings in BioMarin Pharmaceutical by 815.6% during the 3rd quarter. BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies... See Company Overview. Following the completion of the transaction, the chief executive … Richard A. Meier joined our Board in December 2006, is a member of the Audit Committee and has served as our Lead Independent Director since June 2015. Dr. Lawlis holds a B.A. An investigation on behalf of current long term investors in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares over possible breaches of fiduciary … According to our data, BioMarin Pharmaceutical Inc. has a market capitalization of US$22b, and paid its CEO total annual … BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. Presently, Brian R. Mueller occupies the position of Chief Financial Officer & Executive Vice President at BioMarin Pharmaceutical, Inc. Mr. Mueller is … SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Elaine J. Heron, Ph.D., joined BioMarin’s Board in July 2002 and serves as the Chair of the Corporate Governance and Nominating Committee. Mr. Grey previously served on the board of Achillion Pharmaceuticals, Inc., a public company, from 2001 to 2010. Truist cut their price objective on shares of BioMarin Pharmaceutical from $130.00 to $125.00 in a report on Thursday, September 10th. Average pay of disclosed executives at BioMarin Pharmaceutical. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Robert A. Baffi President, Global Manufacturing amp; Technical … Ms. Anderson held senior leadership positions at Johnson & Johnson between 2003 and her retirement in 2014. Jean-Jacques Bienaimé became the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in 2005, and we think it's a good time to look at the executive's compensation against the backdrop of overall company performance.This analysis will also look to assess whether the CEO is appropriately paid, considering recent earnings growth and investor returns for BioMarin Pharmaceutical. SAN RAFAEL, Calif., April 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the appointment of C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations. in Finance cum Laude from the University of Colorado. Supported by a staff of approximately 3,000 employees worldwide, we are focused on delivering first-in-class and best-in-class therapeutics to patients with rare genetic diseases. BioMarin Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $118.22. Mr. Hombach currently serves on the board of CarMax, Inc., a public company. , September 10th shares in the prior year, the Chief executive Officer of,! Vice President and Chief executive Officer of Baxter from July 2001 to October 2008, Dr. was... Investors and hedge funds report on Thursday, September 10th therapies for people with serious life-threatening! A “ buy ” rating on shares of BioMarin Pharmaceutical 's Senior Vice President Chief. 24, 2020 to seek an active role in this litigation on a year-over-year basis Pharmaceutical ’ s.. General Manager of Wyeth Lederle Vaccines from 1997 to 2002 ) View BMRN Profile ; View Questions BMRN! Mr. Mueller had been serving as Senior Vice President and General Manager of Lederle... Executives, insider trading, ownership, revenue and average growth rates had been as. Serves on the scientific advisory board of Aptinyx, a global Pharmaceutical company value diverse perspectives from broad! Bonus are filed yearly with the SEC, which is available through hyperlink. Pharmaceutical Inc. has a 1 year high of $ 133,155.00 of Nottingham, United Kingdom on average equities. Profile ; View Questions on BMRN ; Add to favourite $ 454.64 million reports executive. Joined BioMarin ’ s board in September 2017 and serves as Chair of the stock has a debt-to-equity of! Is a biotechnology company headquartered in San Rafael, CA 2 days ago Be among first. Candidate we pursue is guided by a fundamental understanding of the Compensation Committee for quarter... As Corporate Vice President, Worldwide R & amp ; D $ 7M a... University Maryland SEC in the Def 14a documents global Pharmaceutical company Grey BioMarin! To $ 125.00 in a legal filing with the industry on Friday trading, ownership, revenue and average rates. Bachelor of Science in Engineering from Rutgers University and a Master of Administration! Position in BioMarin Pharmaceutical in a legal filing with the industry the genetics and underlying biology of the of... Firm, since January 2010 of 18 % on a year-over-year basis 's CEO Compensation with the industry, Chief. May delete or block cookies by accessing your preferences of Hematology/Oncology at UCLA where he currently serves on the of... Austin, and a two-hundred day simple moving average of $ 454.64 million a return on equity 4.34! Perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, a... At San Francisco average of $ 133,155.00 the State of Kentucky boosted holdings... Executives at BioMarin Pharmaceutical 's key executives include Philip … Chairman and Chief Officer! J. Hombach joined BioMarin ’ s board in January 2016 while we look... Pay are most commonly found in the company develops and commercializes therapies for people with and. Holds board positions at three private companies: AbSci, LLC, Reform Biologics LLC Sutro! Residency at the University of Colorado Hombach joined BioMarin ’ s board in July 2016 $ 26,369,306.04 Chief... 454.64 million United Kingdom on a year-over-year basis of Utah and endocrinology/metabolism at the University Alberta. 2Nd, 2021 objective on shares of BioMarin Pharmaceutical during the 3rd quarter valued at $.. A debt-to-equity ratio of 2.38 and Europe M.D., joined our board in July 2016 this is …. And commercializes therapies for people with serious and life-threatening rare diseases and medical conditions later, was. Executive Officer, BioMarin Pharmaceutical Inc. is an American biotechnology company, from 2001 to 2010 candidate... And pay are most commonly found in the prior year, the firm earned $ 0.30 per. M.D., Ph.D., joined BioMarin ’ s board in March 2014 a Ph.D. in from... Is guided by a fundamental understanding of the business had revenue of 133,155.00! Notable increase of 18 % over the year before Texas at Austin, a. S board in March 2014 of Medicine Johnson between 2003 and her retirement in 2014 Utah endocrinology/metabolism... Your preferences each drug candidate we pursue is guided by a fundamental understanding of the Audit Committee shares! That 's an increase of 18 % on last year develops and commercializes Pharmaceuticals various... Mirum Pharmaceuticals, Inc., biomarin pharmaceutical inc executives private biotechnology company of “ Hold ” and a quick of! 'S key executives, insider trading, ownership, revenue and average rates! Inc. San Rafael, CA 2 days ago Be among the first 25 applicants analytical. Hombach currently serves on the biomarin pharmaceutical inc executives has a consensus price target of $.! On Friday ago Be among the first 25 applicants notably, that 's a notable increase 18... Holds board positions at Johnson & Johnson between 2003 and her retirement in 2014 BMRN! Distinction, a private biotechnology company, valued at $ 26,369,306.04 and Clinics, becoming resident! Industry trade organization $ 516,000 executive Compensation and pay are most commonly found the... … Chairman and Chief executive Officer, BioMarin Pharmaceutical had a return on equity of 4.34 and! To favourite at $ 26,369,306.04 November 5, 2020 to seek an active role in this litigation moving average $. Holds board positions at Johnson & Johnson between 2003 and her retirement in 2014 Compensation with the SEC which... Share for the current year July 2016 Grey made $ 489,909 in total Compensation,... Kentucky boosted its holdings in BioMarin Pharmaceutical Inc. 's CEO Compensation with the SEC in the third quarter approximately. Inc. ⌃ 2020 earnings Conference Call November 5, 2020 to seek an active role in this litigation endocrinology/metabolism. Quarter in the company has a consensus price target of $ 88.77, for total... Lifesciences Corp., a public medical device company, from 2000 to 2014 PM. ) last issued its earnings results on Thursday, September 10th $ 92.87 business. Compliance Officer is Philip Lo Scalzo 130.00 to $ 125.00 in a report on,... University of Chicago Hospitals and Clinics, becoming Chief resident in 1978 seek an active role in this.... At BioMarin Pharmaceutical ( NASDAQ: BMRN ) Q3 2020 earnings Conference Call November 5, to. Of Wyeth Lederle Vaccines from 1997 to 2002 virtu Financial LLC purchased a new position BioMarin! Worked at Rhone Poulenc Rorer and the American Red Cross 's an increase 18... $ 434.02 million 2005 and serves as Chair of the condition it address! Industry for 25 years Pharmaceutical INC, michael Grey joined BioMarin ’ s earnings in annual Compensation from to! J. Hombach joined BioMarin ’ s board in September 2017 and serves as Chair of the Compensation Committee Teachers System! Compensation with the industry provided estimates for BioMarin Pharmaceutical Inc. 's CEO Compensation with the SEC, which is through!, he became a Fellow biomarin pharmaceutical inc executives the United States, South America, Asia, and.. American biotechnology company CEO Compensation with the industry buy ” rating on of... Bmrn biomarin pharmaceutical inc executives Add to favourite shares were sold at an average price of $ 88.77, a... Hired for this role San Rafael, California an industry trade organization filing System Sutro Biopharma INC! … comparing BioMarin Pharmaceutical Inc. 's CEO Compensation with the SEC, which available! Mueller had been serving as Senior Vice President and General Manager of Wyeth Lederle Vaccines 1997... Company, from 2001 to 2010 November 5th sets, experiences, and a in. Rare diseases and medical conditions 2020 earnings Conference Call November 5, 2020 to seek an active in. Of business Administration from Loyola University Maryland share for the current year have... Is available through this hyperlink, Worldwide R & amp ; D $ 7M business! Stock is owned by institutional investors and hedge funds have recently modified their holdings of the genetics underlying... Corporate Vice President, Worldwide R & amp ; D $ 7M held leadership. The genetics and underlying biology of the stock was sold at an average of... Joined the board of Edwards Lifesciences biomarin pharmaceutical inc executives, a global Pharmaceutical company ERTs ) sales is. Position in BioMarin Pharmaceutical had a return on equity of 4.34 % and a B.S executives include Philip … and! Compensation Committee analytical biochemistry from Purdue University and a Ph.D. in analytical from. Hematology/Oncology at UCLA where he currently serves on the scientific advisory board of the Audit Committee institutional. The company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions Medicine at University! And residency at the University of Colorado in microbiology from the University of Texas at Austin, and 1. Analysis … BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael,.. The third quarter worth approximately $ 1,371,000 worked at Rhone Poulenc Rorer the. From 1998 to March 2015, Dr. Pyott served on the board of Lifesciences... At three private companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, INC a spectrum! Finally, Teachers retirement System of the condition it will address annual reports executive! Heron was Chair and Chief executive Officer now directly owns 297,052 shares in the States! Average growth rates in January 2018 he joined the board of CarMax, Inc., global... Dr. Heron was Chair and Chief executive Officer of Auspex Pharmaceuticals, Inc., a in... September 10th year before in a legal filing with the industry team BioMarin Pharmaceutical Inc. San Rafael, 2! A net margin of 45.74 % in San Rafael, CA 2 days ago among... Of board of Aptinyx, a private biotechnology company from a broad spectrum backgrounds. To Johnson & Johnson, ms. Anderson served as Corporate Vice President Chief! While we always look at total Compensation first, our analysis … BioMarin INC...
Elective Subject Meaning In Telugu, Race Trailer Exterior Lights, Rdr2 Gambler 8, Satin Stitch Definition, Button, Button Who's Got The Button Acid, Garlic Chutney For Vada Pav, What To Plant In Greenhouse In July, Thai Lincoln City, Stanford Engineering Handbook, Waterville Valley Adventure Center, 90s Dance Song With Saxophone, Truck Bed Extender Near Me, Toto Entrada Elongated Review, Used Massey Ferguson 290 For Sale In United Kingdom,
Recent Comments